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Abstract 1 
Cushing’s syndrome is a severe endocrine disorder of cortisol excess, associated with major 2 
metabolic and cardiovascular sequelae. We recently identified somatic mutations in the gene 3 
(PRKACA) encoding the catalytic  (C) subunit of protein kinase A (PKA) to be responsible 4 
for cortisol-producing adrenocortical adenomas (CPAs), which are a major cause of 5 
Cushing’s syndrome. In spite of previous studies on the two initially identified mutations 6 
(L206R, 199_200insW), the mechanisms of action of the clinically highly relevant PRKACA 7 
mutations remain poorly understood. Here, by investigating a large panel of PRKACA 8 
mutations including all those identified so far in Cushing’s syndrome, we unexpectedly find 9 
that not all mutations interfere with the binding of regulatory (R) subunits as previously 10 
hypothesized. Since several mutations lie in a region of PKA C involved in substrate 11 
recognition, we have investigated their consequences on substrate specificity by quantitative 12 
phosphoproteomics. We find that all three mutations analyzed (L206R, 200_201insV and 13 
d244-248+E249Q) cause major changes in the preference of PKA for its targets, leading to 14 
hyperphosphorylation of several PKA substrates, including most notably histone H1.4 at 15 
Ser36, which is required for and promotes mitosis. This is reflected by a 9-fold 16 
hyperphosphorylation of H1.4 in CPAs carrying the L206R mutation. Thus, our findings 17 
suggest that besides hampering binding to R subunits, PRKACA mutations act via altering 18 
PKA substrate specificity. These findings shed new light on the molecular events leading to 19 
Cushing’s syndrome and provide an illustrative example of how mutations altering substrate 20 
specificity of a protein kinase might cause human disease.  21 
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Introduction 22 
Cushing’s syndrome is an endocrine disease characterized by cortisol excess. If not 23 
promptly recognized and treated, it is associated with severe morbidity and increased 24 
mortality, mostly due to metabolic and cardiovascular sequelae, such as diabetes mellitus, 25 
osteoporosis and hypertension (1,2). Beside ACTH-producing pituitary adenomas, cortisol-26 
producing adenomas of the adrenal are the major cause of endogenous Cushing's 27 
syndrome (3).  28 
Protein kinase A (PKA) is the main intracellular mediator of the ubiquitous second 29 
messenger cyclic AMP (cAMP), which is produced in response to several hormones and 30 
neurotransmitters (4,5). In its inactive state, PKA is a tetrameric complex composed of two 31 
regulatory (R) and two catalytic (C) subunits (5), which exist in different isoforms  three for 32 
C (, , ) and four for R (I, I, II, II) subunits, each encoded by a separate gene (6). 33 
Additionally, protein kinase X (PrKX) can also form holoenzymes with R subunits (7). In the 34 
inactive complex, two short linear segments emanating from each R subunit, known as 35 
inhibitory sequences, act as substrates (RII) or pseudo-substrates (RI) that occupy the active 36 
site clefts of the C subunits, thus preventing the access of other substrates (5,8,9); this 37 
keeps PKA in the inactive state (5,8,9). Binding of cAMP to two distinct sites on each R 38 
subunit induces their dissociation from the C subunits, allowing the C subunits to 39 
phosphorylate a large number of PKA substrates located in both the cytosol and the nucleus 40 
(5,8,9). 41 
Our group has recently discovered that somatic mutations in the gene coding for the C 42 
subunit of PKA (PRKACA) are responsible for Cushing´s syndrome due to cortisol-producing 43 
adrenocortical adenomas (CPAs) (10-13). These findings have been independently 44 
confirmed by other groups (14-18). Very recently, rare mutations in the gene coding for the 45 
C subunit of PKA (PRKACB) have also been found in CPAs (19). Between 23 and 67% of 46 
all CPAs carry a recurrent mutation (L206R) of a residue in the C subunit that is involved in 47 
the interaction with the R subunits (10,11,14-16). By screening a large group of CPAs, we 48 
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have in the meantime identified six additional PRKACA mutations (199_200insW, 49 
S213R+insIILR, 200_201insV, W197R, d244-248+E249Q and E32V) in unilateral adenomas 50 
of patients affected by overt Cushing’s syndrome (10-12). With one exception (E32V), all 51 
identified mutations lie in a hot spot region on the surface of the C subunit that is adjacent 52 
to the active site cleft and faces the R subunit (12). 53 
Whereas all previous studies provide strong evidence for a causal role of PRKACA 54 
mutations, the mechanisms linking these mutations to increased cell proliferation and cortisol 55 
secretion in adrenocortical cells are still debated (10,14-16). One of the initial studies 56 
suggested that the L206R mutation increases PKA activity by enhancing substrate 57 
interaction and/or the catalytic activity of the enzyme (14). In contrast, two other studies 58 
suggested that the L206R mutation might prevent binding of the R subunit (15,16). In strong 59 
support of this possibility, we subsequently demonstrated that the two initially identified 60 
mutations (L206R and 199_200insW) interfere with the formation of a stable complex with R 61 
subunits, thus rendering mutated C subunits constitutively active (13). However, we did not 62 
observe increased catalytic activity (13). Whereas these data indicate that a reduced 63 
interaction with R subunits is likely involved in the pathogenesis of Cushing’s syndrome – at 64 
least in the case of the two investigated PRKACA mutations (L206R and 199_200insW) – 65 
additional mechanisms might play an equally important role. 66 
Here, we report a comprehensive functional characterization of all PRKACA mutations 67 
identified so far. Unexpectedly, our results indicate that besides interfering with the binding 68 
of R subunits, PRKACA mutations cause major changes in the preference of PKA for its 69 
targets, leading to hyperphosphorylation of several PKA substrates, including most notably 70 
histone H1.4 at Ser36, which is required for and promotes mitosis (20).  71 
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Methods 72 
Plasmids 73 
Plasmids encoding human RI, RIIβ and RII-FLAG were described earlier (13). A plasmid 74 
encoding human wild-type C was purchased from Origene. Mutations in the coding 75 
sequence of C were introduced by PCR as previously described (10). To generate a 76 
plasmid encoding a FLAG-tagged RI subunit, a fragment containing the entire coding 77 
sequence of the human RI subunit was amplified by PCR with a forward primer containing 78 
the FLAG tag (amino-acid sequence DYKDDDDA) and a HindIII site at the 5’ and a reverse 79 
primer containing a NotI site at the 3’. This fragment was subsequently cloned between the 80 
HindIII and NotI sites of pcDNA3. 81 
 82 
Tumor tissue 83 
A total of 8 snap-frozen tumor specimens from CPAs were investigated. All samples were 84 
collected at the University Hospital of Würzburg. Six of these samples had been included in 85 
previous reports from our group: three in Ronchi et al. (12) and three in Beuschlein et al. 86 
(10). According to our previous sequencing data, four CPA samples harbored somatic 87 
PRKACA mutations. In particular, three samples from patients with overt Cushing´s 88 
syndrome presented a L206R substitution and one sample from a patient with mild 89 
autonomous cortisol secretion (subclinical Cushing´s syndrome) presented a d244-90 
248+E249Q mutation. The four remaining CPAs were PRKACA wild-type. The collection of 91 
the clinical data and the biomaterial for this retrospective study was approved by the ethics 92 
committee of the University of Würzburg (approvals no. 93/02 and 88/11). Written informed 93 
consent was obtained from all patients. 94 
 95 
Cell culture and transfection 96 
HEK293A cells were obtained from ATCC. Cells were cultured in Dulbecco´s modified 97 
Eagle’s medium (DMEM) supplemented with 10% FCS, 0.1 mg/ml streptomycin and 100 98 
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U/ml penicillin at 37 °C, 5% (vol/vol) CO2. HEK293A cells were seeded at a density of 99 
3.5x106 cells/15-cm Petri dish, 1.2 x 106 cells/10-cm Petri dish or 0.25 x 106 cells/well onto 6-100 
well plates and allowed to grow for 24 h, after which they were transfected with the Effectene 101 
transfection kit (Qiagen) according to the manufacturer´s protocol. A 1:8 ratio of transfected 102 
C and R subunit DNAs was used to favor association between C and R subunits (10). All 103 
experiments were performed 48 h after transfection. For SILAC labeling, the cells were 104 
grown in light (Lys0, Arg0) or heavy (Lys8, Arg10) labeled DMEM supplemented with 10% 105 
dialyzed FCS and 0.1 mg/ml streptomycin and 100 U/ml penicillin for at least 6 passages 106 
before the experiment. 107 
 108 
Preparation of cell lysates 109 
Cells were washed with ice-cold phosphate-buffered saline (PBS), scraped off plates, and 110 
resuspended in 300 l 5/2 buffer (5 mM Tris-HCl, 2 mM EDTA, pH 7.4). Thereafter, samples 111 
were homogenized using an Ultraturrax device for 20 s on ice and centrifuged at 50,000 x g 112 
for 30 min at 4 °C to remove membranes. 113 
 114 
Preparation of total cell lysates 115 
Cells were washed once with PBS. Then, 2 ml of lysis buffer (8M urea, 1 mM sodium 116 
vanadate, 2.5 mM pyrophosphate, 1 mM -glycerophosphate, 20mM HEPES, pH 8.0) 117 
supplemented with the cOmplete Mini EDTA-free protease inhibitor cocktail (Roche) were 118 
added to each 15-cm Petri dish and the cells were scraped into the buffer. Cell suspensions 119 
were sonicated three times for 15 sec each and lysates were cleared by centrifugation at 120 
4,000 rpm for 1 h at 15 °C. 121 
 122 
PKA activity assay 123 
PKA catalytic activity was measured on cell lysates using the PepTag non-radioactive 124 
cAMP-dependent protein kinase assay (Promega), which uses fluorescent kemptide as a 125 
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substrate, following the manufacturer´s instructions. Images of the gels were acquired with a 126 
gel documentation system (Herolab) and analyzed using the ImageJ software 127 
(http://rsbweb.nih.gov/ij). Endogenous PKA activity was subtracted and values were 128 
normalized to the value of the stimulated wild-type. 129 
 130 
Co-immunoprecipitation 131 
Cells were lysed with a buffer containing 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% 132 
Triton X-100, 20 mM Tris-HCl, pH 7.5, supplemented with cOmplete Mini protease inhibitor 133 
cocktail (Roche). Lysates were centrifuged at 20,000 x g for 10 min at 4 °C. Supernatants 134 
were transferred to a new vial and incubated with protein-A sepharose for 2 h at 4 °C under 135 
continuous rotation. Protein-A sepharose was preincubated with a mouse monoclonal anti-136 
FLAG antibody (Sigma-Aldrich, # F3165). Preincubations were performed overnight at 4 °C 137 
under continuous rotation. After the incubation of protein-A sepharose with the cell lysates, 138 
samples were washed 5 times with lysis buffer. Proteins were recovered from protein-A 139 
sepharose by addition of Laemmli buffer, followed by incubation at 95 °C for 3 min. After 140 
Western blot analysis and quantification, the amount of C was normalized to that in the 141 
wild-type sample. 142 
 143 
Histone extraction 144 
Histones were acid-extracted from cells and CPA samples as described by Shechter et al. 145 
(21). Briefly, harvested cells or Douncer-homogenized tissue samples were lysed in a 146 
hypotonic lysis buffer (150 mM Tris/HCl, 1 mM KCl, 1.5 mM MgCl2, 1 mM DTT, pH 8.0) 147 
supplemented with 0.5 μg/ml leupeptin, 2 μg/ml aprotinin, 0.1 mM phenylmethylsulfonyl 148 
fluoride (PMSF), the cOmplete Mini protease inhibitor cocktail (Roche) and a phosphatase 149 
inhibitor cocktail (Roche). Lysates were then acid-extracted with H2SO4 for 30 min followed 150 
by precipitation with trichloroacetic acid and resuspension in H2O. 151 
 152 
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Western blot analysis 153 
Samples were mixed with Laemmli buffer and incubated at 95 °C for 3 min. Proteins were 154 
separated by electrophoresis on either a 10% or 15% (for histone H1.4) SDS polyacrylamide 155 
gel and electro-transferred to a PVDF membrane (Merck Millipore). Membranes were 156 
blocked with Tris-buffered saline supplemented with 1% Tween and 5% skim milk powder or 157 
bovine serum albumin (antibodies detecting phosphoproteins) for 1 hour at RT, and 158 
incubated overnight at 4 °C with the indicated primary antibody, followed by incubation with 159 
horseradish peroxidase-conjugated secondary antibodies for 1 h at RT. PKA C subunits 160 
were detected with a rabbit polyclonal antibody (Cell Signaling #4782, 1:7,000 dilution). 161 
FLAG-tagged R subunits were detected using a rabbit monoclonal anti-FLAG antibody 162 
(Sigma-Aldrich, #F7425, 1:4,000 dilution). PKA RI subunits were detected using a mouse 163 
monoclonal antibody (BD Transduction Lab., #610609, 1:1,000 dilution) and RII subunits 164 
with a mouse monoclonal antibody (BD Transduction Lab., #610625, 1:2,000 dilution). 165 
Phosphorylated PKA substrates were detected using a rabbit polyclonal antibody (Cell 166 
Signaling, #9621, 1:1,000 dilution). A rabbit polyclonal antibody (ThermoFisher, #PA5-167 
31908, 1:2,000 dilution) and a rabbit polyclonal antibody (ThermoFisher, #PA5-31907, 168 
1:1,000 dilution) was used for total histone H1.4 and Ser36 phosphorylated histone H1.4, 169 
respectively. 170 
 171 
Substrate specificity of PKA Cmutants in silico 172 
The in silico prediction was done using the Kinase Substrate Prediction v 2.0 algorithm (22). 173 
This algorithm predicts substrate specificity based on the primary amino acid sequence of 174 
more than 488 human protein kinase catalytic domains and 10,000 known kinasesubstrate 175 
phosphosite pairs. The algorithm computes a specificity matrix for a given kinase, or mutant 176 
thereof, where values indicate the relative preference for each amino acid at each position 177 
around the phosphoacceptor site. Only relevant changes are reported. 178 
 179 
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Substrate specificity of PKA Cmutants in vitro 180 
Mutant and wild-type samples were labelled with heavy and light amino acids as described 181 
in cell culture and transfection. Before preparing total cell lysates, the cells were stimulated 182 
with 10 M forskolin for 30 min. Protein concentration of the total cell lysates were 183 
determined using the BCA assay. Before processing the samples for phosphoproteomics, an 184 
input sample for proteome analysis was taken, which was digested with trypsin and analysed 185 
by nano LC-MS/MS. For phosphoproteomics experiments, no more than 20 mg protein were 186 
used. Substrate specificity was assessed using the PTMScan Phospho-PKA Substrate Motif 187 
(RRXS*/T*) Kit (Cell Signaling, #5565) following the manufacturer´s instructions – see 188 
Supplementary Data (23) for details. The dried peptides were stored at -20°C until the nano 189 
LC-MS/MS analysis. 190 
 191 
Nano LC-MS/MS analysis  192 
Nanoscale liquid chromatography coupled to tandem mass spectrometry (nano LC-MS/MS) 193 
analyses were performed on an Orbitrap Fusion system (Thermo Scientific) equipped with 194 
an EASY-Spray Ion Source and coupled to an EASY-nLC 1000 (Thermo Scientific). 195 
Peptides, resuspended in 2% acetonitrile and 0.1% formic acid, were loaded on a trapping 196 
column (2 cm x 75 µm ID, PepMap C18, 3 µm particles, 100 Å pore size) and separated on 197 
an EASY-Spray column (50 cm x 75 µm ID, PepMap C18, 2 µm particles, 100 Å pore size) 198 
with a 140-min linear gradient from 3% to 45% acetonitrile and 0.1 % formic acid.  199 
Both MS and MS/MS scans were acquired on the Orbitrap analyzer with a resolution of 200 
60,000 for MS scans and 15,000 for MS/MS scans. HCD fragmentation with 35% normalized 201 
collision energy was applied.  A Top Speed data-dependent MS/MS method with a fixed 202 
cycle time of 3 s was used. Dynamic exclusion was applied with a repeat count of 1 and an 203 
exclusion duration of 60 s; singly charged precursors were excluded from selection. 204 
Minimum signal threshold for precursor selection was set to 5 x 104. Predictive AGC was 205 
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used with AGC target values of 2 x 105 for MS scans and 5 x 104 for MS/MS scans. EASY-IC 206 
was used for internal calibration. 207 
 208 
Raw data processing and database search 209 
For raw-data processing, database searches and SILAC quantification, the MaxQuant 210 
software version 1.5.6.5 was used (24). The search was performed against the human 211 
UniProt reference proteome database (download date: 2016-12-09) plus a small database 212 
containing known immunoglobulin chains. Additionally, a database containing common 213 
contaminants (included in MaxQuant) was used. The search was performed with tryptic 214 
cleavage specificity and 3 allowed miscleavages. Results were filtered to a false-discovery 215 
rate (FDR) <1% on protein, peptide and phosphosite level and for modified peptides a 216 
minimum score of 40 and a minimum delta score of 6 were required. In addition to default 217 
settings, protein N-terminal acetylation, Gln to pyro-Glu formation (N-term. Q), oxidation (M) 218 
and phosphorylation (STY) were included as variable modifications; carbamidomethyl (C) 219 
was set as fixed modification. For SILAC quantification, light (Arg0/Lys0) and heavy 220 
(Arg10/Lys8) labeling were selected, with max. 4 labeled amino acids per peptide allowed; 221 
matching between runs was disabled.  222 
For further data analysis in R, the MaxQuant “Phospho (STY) Sites” table was processed, 223 
and only phosphosites with a localization probability >0.75 and a PEP < 0.05 have been 224 
included. For each experiment, the distribution of log2-transformed heavy/light SILAC ratios 225 
were normalized to the first mode of the distribution. Data from replicate experiments were 226 
combined, and Student´s t-test as well as limma p-values were calculated and corrected for 227 
multiple-hypothesis testing (Benjamini-Hochberg algorithm, FDR). In addition, boxplot 228 
outliers with values outside of the 1.5x and/or the 3x interquartile range (IQR) of the 1st or 229 
3rd quartile (Q1 or Q3) were labeled as significant or highly significant, only if a replicate 230 
notch, defined as 1.58*IQR/sqrt(number of experiments), was not overlapping with the 231 
median of all such notches. 232 
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 233 
Motif logo 234 
For calculation of position weight matrices from the phosphoproteomics data, the web tool 235 
plogo (http://plogo.uconn.edu/) (25) was used. Values were calculated relative to the 236 
background amino acid frequencies in the human proteome. Motif logos were then 237 
generated using the Weblogo software version 3.5.0 (26).  238 
 239 
Structures 240 
Protein structures were generated using PyMol version 1.7.4.5. PDB entries 3TNP (9) and 241 
3TNQ (9) were used as templates for the structures of the PKA C -RII holoenzyme and 242 
the C subunit in complex with a phosphorylated substrate, respectively. 243 
 244 
Statistical analyses 245 
Statistical analyses were performed using the Prism 6 software (GraphPad). Values are 246 
given as mean ± s.e.m. Differences between two groups were assessed by two-tailed 247 
Student’s t-test. Differences among three or more groups were assessed by two-way 248 
analysis of variance (ANOVA), followed by Bonferroni’s post hoc test. Differences were 249 
considered significant for P values < 0.05.  250 
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Results 251 
PRKACA mutations have variable effects on R subunit binding 252 
Through genetic screening of a large series of CPAs from patients with Cushing´s syndrome, 253 
we have identified a total of 7 PRKACA mutations, including the most frequent L206R, with 254 
an overall prevalence in CPAs of about 40% (10-12). The results of all available studies to 255 
date are summarized in Table 1. With the exception of E32V, all mutations identified so far 256 
lie at a hot spot at the interface with the R subunit (Fig. 1). Since our previous data indicated 257 
that the two initially identified mutations (L206R and 199_200insW) interfere with the 258 
formation of a stable complex with the inhibitory RII subunit (13), we first evaluated the 259 
interaction of all mutations identified so far with both RI and RII  the two main R subunit 260 
isoforms expressed in adrenocortical cells  by co-immunoprecipitation (Fig. 2 and 261 
Supplementary Data, Fig. S1 (23)).  262 
As expected, we observed a robust co-immunoprecipitation of exogenously expressed wild-263 
type C with both RI and RII (Fig. 2 and Supplementary Data, Fig. S1 (23)). In the case 264 
of four mutants (199_200insW, L206R, 200_201_insV and S213R+insIILR), we detected 265 
only faint signals in the presence of either RI or RII, indicating that the interaction with 266 
both R subunit isoforms was largely lost, consistent with our previous observations (13). 267 
Unexpectedly, however, two mutants (W197R and E32V) displayed normal binding to both 268 
RI and RII (Fig. 2, arrows). Of note, a previous report indicates that the W197R mutant 269 
cannot bind to R subunits unless they are stripped off of cAMP, a condition that is not 270 
occurring in intact cells (27). The d244-248+E249Q mutant had an interesting behavior as it 271 
showed normal binding to RII but a complete lack of binding to RI(Fig 2, arrow)With the 272 
exception of S213R+insIILR, all C mutants dissociated virtually completely from R subunits 273 
upon addition of cAMP (Fig. 2 and Supplementary Data, Fig. S1 (23)). 274 
 275 
PRKACA mutations have variable effects on PKA activity 276 
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Next, we investigated the activity of the C mutants against the widely used synthetic 277 
peptide substrate kemptide. In lysates obtained from HEK293A cells co-transfected with 278 
wild-type or mutant C subunits and either RI or RII, we observed a high variability among 279 
the investigated C mutants. A first group of mutants (199_200insW, L206R, W197R, d244-280 
248+E249Q and S213R+insIILR) was characterized by increased basal activity against 281 
kemptide at least in one condition (i.e. with RI or RII) (Fig. 3). The E32V mutant was 282 
apparently behaving like wild-type C (Fig. 3). The 200_201insV mutant was characterized 283 
by a strongly reduced maximal activity (measured in the presence of cAMP) against 284 
kemptide compared to wild-type C(Fig. 3). 285 
Unexpectedly, a different picture was observed when PKA activity was evaluated against 286 
endogenous substrates in lysates of HEK293A cells transfected with the different C 287 
mutants and analyzed by Western blot analysis with an anti-phospho-PKA substrate 288 
antibody (Supplementary Data, Fig. S2 (23)). In this assay, RII but not RIco-expression 289 
was capable of buffering the activity of exogenous wild-type or mutant C subunits, 290 
consistent with previous observations (9). Therefore, we focused on the results obtained in 291 
the presence of RII. In cells co-transfected with RII, two C mutants (199_200insW and 292 
L206R) showed strongly increased basal activity compared to wild-type C(Supplementary 293 
Data, Fig. S2 (23)). The remaining mutants were characterized by a variable degree of 294 
increased basal activity compared to wild-type C(Supplementary Data, Fig. S2 (23)). 295 
Notably, in this assay, the 200_201insV mutant, which was characterized by a strongly 296 
reduced maximal activity in the kemptide assay, could be stimulated by addition of the 297 
adenylyl cyclase activator forskolin to a similar although slightly lower extent compared to 298 
wild-type C (Supplementary Data, Fig. S2 (23)). At a closer look, this analysis also 299 
revealed potentially different phosphorylation patterns for the C mutants compared to wild-300 
type C as well as among the C mutants (Supplementary Data, Fig. S2A, arrows (23)). 301 
Altogether, these data suggested the possibility that the investigated PRKACA mutations 302 
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might alter the relative preference of PKA for its substrates, so that investigating a single 303 
synthetic substrate does not provide a satisfactory description of the activity of C mutants 304 
against endogenous substrates. 305 
 306 
In silico analysis of PRKACA mutations predicts changes in substrate specificity 307 
Our results suggested the possibility that PRKACA mutations might alter the preference of 308 
PKA for its substrates and, thus, cause a relative change in substrate specificity. This 309 
hypothesis was consistent with the location of most PRKACA mutations in a region of C 310 
that is critical for substrate binding and recognition (27,28) (Fig. 1B). To further explore this 311 
possibility, we performed an in silico analysis using a protein kinase substrate prediction 312 
algorithm (22). The algorithm predicted relevant changes in substrate specificity for four 313 
mutants: 199_200insW, L206R, d244-248+E249Q and 200_201insV (Fig. 1B and 314 
Supplementary Data, Fig. S3 (23)). The largest change was predicted for the d244-315 
248+E249Q mutant. For the S213R+insIILR mutant, the algorithm predicted only minor 316 
effects on substrate specificity, whereas no changes were predicted for the two remaining 317 
mutants (E32V, W197R).  318 
 319 
Phosphoproteomics reveals major changes in substrate specificity caused by 320 
PRKACA mutations 321 
Motivated by the results of the Western blot analysis and the in silico prediction, we used a 322 
quantitative phosphoproteomics approach to comprehensively analyze and quantitatively 323 
compare the substrate repertoires of wild-type and mutant PKA C in mammalian cells. The 324 
three PKA C mutations predicted to have the largest effects on substrate specificity were 325 
analyzed (Fig. 4). These included the frequent L206R mutation, the d244-248+E249Q 326 
mutation, which was predicted to have the strongest effect on substrate specificity, and the 327 
200_201insV mutation, which shared prediction with the adjacent 199_200insW mutation. All 328 
cell lysates were obtained after 30-min stimulation with the adenylyl cyclase activator 329 
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forskolin to allow comparison under conditions of maximal PKA activity. The 330 
phosphoproteomics analysis identified 463 sites phosphorylated by the wild-type C subunit. 331 
A direct quantitative comparison between wild-type and mutant C subunits demonstrated 332 
that the investigated PRKACA mutations caused major changes in the pattern of PKA 333 
substrate phosphorylation (Fig. 4). These changes involved 62, 116 and 75 substrates that 334 
were either hyper- or hypophosphorylated by the L206R, d244-248+E249Q and 335 
200_201insV mutants, respectively, compared to wild-type (Fig. 4 and Supplementary Data, 336 
Dataset S1 (23)). Our data also allowed us to compute sequence logos of the region 337 
encompassing the phosphoacceptor site, where the size of the letters, each corresponding 338 
to a given amino acid, indicates their relative frequency at a given position (Fig. 4). Overall, 339 
the analysis showed relevant changes in the preferred amino acids surrounding the 340 
RR/KXpS/T phosphorylation consensus sequence, including an increased preference for 341 
amino acids with small or hydrophobic, non-aromatic side chains (glycine, alanine, valine, 342 
methionine) at position +1 from the phosphoacceptor site, at the expense of phenylalanine 343 
and other amino acids (Fig. 4). Moreover, we observed an increased preference for leucine 344 
at position +1 from the phosphoacceptor site and an increased preference for acidic 345 
residues in the residues downstream of the phosphoacceptor site for the L206R mutant, 346 
consistent with a recent report by Lubner et al. in E. coli (29). Additionally, the L206R mutant 347 
was characterized by a loss of preference for arginine residues at positions -7 to -4 relative 348 
to the phosphoacceptor site and an increased preference for glutamic acid and serine at 349 
several positions. For the d244-248+E249Q mutant, we found an increased preference for 350 
leucine at position -1 from the phosphoacceptor site and a reduced preference for acidic 351 
residues downstream of the phosphoacceptor site. The latter trend was mirrored in the 352 
hypophosphorylated peptides, where acidic residues were overrepresented downstream of 353 
the phosphoacceptor site. Interestingly, both mutants (L206R and d244-248+E249Q) 354 
showed an asymmetric effect on substrate phosphorylation with a higher number of peptides 355 
that were hyperphosphorylated (40 and 93, respectively) compared to a relatively lower 356 
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number of hypophosphorylated ones (22 and 23, respectively). Therefore, both mutations 357 
mainly seemed to increase the phosphorylation of poor substrates of the wild-type enzyme, 358 
while causing only smaller decreases in the phosphorylation of other substrates. For the 359 
200_201insV mutant, we observed an increased preference for leucine and alanine at 360 
position -1, accompanied by a loss of preference for acidic residues downstream of the 361 
phosphoacceptor site and an increased preference for proline at position +3. The loss of 362 
preference for peptides containing acidic residues at downstream positions was reflected by 363 
their relative overrepresentation in the corresponding hypophosphorylated peptides (left 364 
panel). In contrast to the other two mutants, the 200_201insV mutant was characterized by a 365 
rather symmetric distribution with 35 hypo- and 40 hyperphosphorylated peptides, 366 
suggesting that comparable numbers of substrates were either hyper- or 367 
hypophosphorylated. In general, the phosphorylation patterns differed among the three C 368 
mutants. However, four substrates were consistently found to be hyperphosphorylated by all 369 
three mutants compared to wild type. These were the citron rho-interacting kinase (CIT; Ser 370 
480), the mitochondrial import receptor subunit TOM34 (Ser 93), histone H1.2 (Ser 36) and 371 
histone H1.4 (Ser 36) (Fig. 4). H1.2, H1.4, TOM34 and CIT were also found to be present 372 
and phosphorylated at the same sites in lysates of the cortisol-producing adrenocortical cell 373 
line NCI-H295R (Supplementary Data, Dataset S1 (23)). 374 
To rule out that the observed changes were due to changes in protein levels rather than 375 
phosphorylation, we performed an additional proteomics experiment on the same cell 376 
lysates, which allowed us to directly compare the relative amounts of proteins at the 377 
proteome level between wild-type and mutant samples, including, importantly, H1.2, H1.4 378 
and TOMM34 (Supplementary Data, Fig. S4, Dataset S2 (23)). The results indicate that the 379 
levels of most proteins, including H1.2, H1.4 and TOMM34, were unchanged between wild-380 
type and mutant samples. 381 
Whereas hyperphosphorylation of CIT and TOM34 might mediate some effects of PRKACA 382 
mutations, we concentrated our attention on H1 because phosphorylation by PKA of histone 383 
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H1.4 on Ser36  and possibly of the highly homologous Ser36 site on H1.2  is required for 384 
mitosis (20). 385 
 386 
PRKACA mutations cause histone H1.4 hyperphosphorylation in vitro and in CPAs 387 
The conserved Ser36 phosphorylation site on histone H1 isoforms has been implicated in 388 
chromatin condensation and mitosis (20). This has been better studied for histone H1.4, 389 
which has been shown to be phosphorylated by PKA on Ser36 during mitosis, an event that 390 
has been demonstrated to induce histone H1.4 dissociation from chromatin and be required 391 
for mitosis (20). Because of the potential relevance of histone H1 Ser36 phosphorylation for 392 
the mechanism of action of PRKACA mutations, we first investigated histone H1.4 393 
phosphorylation in HEK293A cells transfected with C subunit mutants. In HEK293A cells, 394 
overexpression of the L206R mutant caused a strong increase (12-fold under basal 395 
conditions; 3-fold in the presence of forskolin) in histone H1.4 Ser36 phosphorylation 396 
compared to overexpression of wild-type C (Fig. 5 and Supplementary Data, Fig. S5 (23)). 397 
Modestly increased levels of histone H1.4 Ser36 phosphorylation were also observed with 398 
the d244-248+E249Q and 200_201insV mutants compared with wild-type C, even though 399 
these differences did not reach statistical significance (Fig. 5 and Supplementary Data, Fig. 400 
S5 (23)).  401 
Furthermore, we analyzed histone H1.4 Ser36 phosphorylation in human CPA tumor 402 
samples of patients with Cushing´s syndrome with or without PRKACA mutations (summary 403 
of clinical data in Supplementary Data, Table S1 (23)). Importantly, a 9-fold increase in 404 
histone H1.4 Ser36 phosphorylation was observed in CPAs carrying the L206R mutation 405 
compared with CPAs without PRKACA mutations (1.9±0.26 vs. 0.21±0.29, p=0.009) (Fig. 6). 406 
These results indicated that in patients with adrenal Cushing´s syndrome, at least the by far 407 
most frequent L206R mutation is associated with a strong increase of H1.4 phosphorylation 408 
in the patients´ tumor tissue.  409 
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Discussion 410 
Our results indicate that PRKACA mutations found in CPAs alter PKA preference for its 411 
targets, inducing hyperphosphorylation of several PKA substrates, including most notably 412 
histone H1.4 at Ser36, which has been suggested to play an essential role in mitosis (20). 413 
Thus, our study reveals another key mechanism that, together with increased PKA basal 414 
activity, might explain the development of CPAs in the presence of somatic PRKACA 415 
mutations (Supplementary Data, Fig. S6 (23)). 416 
Whereas our previous study on the two PRKACA mutations intially identified in adrenal 417 
Cushing´s syndrome (L206R and 199_200insW) showed that these mutations increase 418 
basal PKA activity by preventing the binding of R subunits, the present results obtained on a 419 
larger group of PRKACA mutations indicate that this is not always the case (see 420 
Supplementary Data, Fig. S7 (23) for a summary of the present results), and that a relative 421 
change in PKA substrate specificity likely contributes to the mechanism of action of PRKACA 422 
mutations. 423 
Our phosphoproteomics analysis revealed four PKA subtrates that were 424 
hyperphosphorylated by all three PKA C mutants analyzed, and, thus, are potentially 425 
involved in the pathogenesis of CPAs due to PRKACA mutations. These included CIT (Ser 426 
480), TOM34 (Ser 93), histone H1.2 (Ser 36) and histone H1.4 (Ser 36). Importantly, all four 427 
substrates were also identified to be expressed and phosphorylated on the same sites in 428 
lysates of NCI-H295R cells, which are widely used as a model of differentiated, cortisol-429 
producing adrenocortical cells (Supplementary Data, Dataset S1 (23)). Of these, histone 430 
H1.4 and the highly homologous histone H1.2 appeared particularly intriguing because H1 431 
histones play an important role in promoting, regulating and maintaining chromatin 432 
organization and, thus, are deeply involved in the regulation of gene transcription and 433 
mitosis (20,30-32). H1 histones possess a conserved serine residue at position 36 (Ser36), 434 
which has been mainly investigated for histone H1.4. Interestingly, histone H1.4 has been 435 
shown to be strongly phosphorylated on Ser36 by PKA at the first stage of mitosis 436 
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(prophase), to then rapidly revert to normal, low phosphorylation levels during cytokinesis 437 
(20). Phosphorylation of histone H1.4 on Ser36 has been shown to promote histone H1.4 438 
dissociation from mitogenic DNA and induce changes in chromatin organization (20). 439 
Moreover, it has been shown that silencing H1.4 inhibits mitosis, an effect that cannot be 440 
rescued by a phosphorylation-deficient H1.4 mutant (S36A) (20). These findings indicate that 441 
the PKA-dependent phosphorylation of histone H1.4 at Ser36 plays an important role in 442 
promoting mitosis, presumably by inducing changes in chromatin structure that are required 443 
for the realization of the mitogenic program (20). Whereas other changes in the PKA 444 
phosphorylation pattern caused by PRKACA mutations might also play a role in the 445 
pathogenesis of CPAs, it is noteworthy that two of the four hyperphosphorylated sites shared 446 
by the three tested C mutants are Ser36 on histone H1.4 and the corresponding Ser36 on 447 
histone H1.2, which likely plays a similar role. Our finding that histone H1.4 is highly 448 
hyperphosphorylated in CPAs carrying the L206R mutation – but not in those with wild-type 449 
PKA – supports a role of H1.4 hyperphosphorylation in the pathogenesis of CPAs due to 450 
PRKACA mutations. Further investigations, such as studies on chromatin organization by 451 
DAPI staining and H1.4–chromatin association by immunofluorescence (20) or chromatin 452 
immunoprecipitation will be required to further clarify the impact of the increased H1.4 453 
(Ser36) phosphorylation on chromatin organization in PRKACA mutated CPA tissue.  454 
In addition to hyperphosphorylation of histone H1, that of CIT and of TOM34 – which, to the 455 
best of our knowledge, have not been previously reported to be phosphorylated by PKA – 456 
might also play a role in the mechanism of action of PRKACA mutations. CIT is a 457 
serine/threonine-protein kinase that has been shown to be required for cytokinesis (33). 458 
Phosphorylation of Ser480 might potentially influence the activity of CIT and, thus, affect 459 
cytokinesis. TOM34 is involved in mitochondrial protein import (34). Interestingly, yeast 460 
TOM70 has been shown to be phosphorylated by PKA on Ser174 (35), which is homologous 461 
to Ser93 in human TOM34. In yeast, TOM70 phosphorylation by PKA inhibits its receptor 462 
activity, which results in reduced mitochondrial import of metabolite carriers (35). 463 
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Phosphorylation of TOM34 at Ser93 could have a similar effect. Future studies will be 464 
required to evaluate the role of CIT and TOM34 in the pathogenesis of CPAs. 465 
The finding that PRKACA mutations cause histone H1.4 phosphorylation might help 466 
explaining why these mutations lead to the development of CPAs, while normal cAMP/PKA 467 
signaling such as resulting from physiological stimulation by the adrenocorticotropic 468 
hormone (ACTH) has no or at most only mild proliferative effects on adrenocortical cells 469 
(36,37). Intriguingly, this may suggest that whereas an increase in PKA activity might be 470 
sufficient to induce excess cortisol production in the presence of PRKACA mutations, a 471 
change in PKA substrate preference – and the resulting hyperphosphorylation of histone 472 
H1.4 and possibly other targets involved in the control of cell replication – might be required 473 
to stimulate cell proliferation. 474 
Finally, our findings indicate that, given the important changes in substrate specificity caused 475 
by PRKACA mutations, it might be possible to develop selective orthosteric PKA inhibitors 476 
that bind only to the mutant C subunits and, thus, selectively inhibit the mutated PKA in 477 
CPAs without affecting the function of wild-type PKA in normal cells. 478 
In summary, our findings indicate that PRKACA mutations found in CPAs lead to a change in 479 
the pattern of PKA phosphorylation, which might play an important role in their mechanism of 480 
action. This not only reveals a novel key mechanism potentially involved in the pathogenesis 481 
of CPAs and Cushing’s syndrome, but might also allow the development of selective PKA 482 
inhibitors for therapeutic purposes that block mutated but not wild-type PKA. Moreover, 483 
these findings provide a highly illustrative example of how mutations altering substrate 484 
specificity of a protein kinase might cause a human disease, which might also have 485 
implications for other conditions. 486 
  487 
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Figure legends 
Fig. 1. Somatic PRKACA mutations identified in adrenal Cushing´s Syndrome. (A) 
Location of the identified PRKACA mutations in the crystal structure of the PKA holoenzyme. 
Note the clustering of the PRKACA mutations at the interface with the R subunit. The 
structure of the RII2:C2 holoenzyme (Protein data bank/PDB entry 3TNP) was used as 
template. (B) Enlarged view of the PKA C-RII interface. Shown are the positions of 
residues affected by PRKACA mutations relative to the inhibitory sequence of RII in the 
PKA RII2:C2 holoenzyme. The inhibitory sequence of RII interacts with active site cleft of 
C and acts as a PKA substrate. Note the phosphorylated serine (S) residue within the 
canonical consensus for PKA phosphorylation (RRXS) in the inhibitory sequence. Most 
residues affected by PRKACA mutations participate directly or indirectly in substrate 
recognition. *, Residues affected by PRKACA mutations with largest predicted effects on 
substrate specificity based on in silico analysis. PDB entry 3TNQ was used as template. 
 
Fig. 2. Effect of PRKACA mutations on the association of C with R subunits. 
HEK293A cells were co-transfected with FLAG-tagged RIIor RI and either wild-type (WT) 
or mutant C subunits. The association between C and R subunits in the absence or 
presence of cAMP (200 M) was analyzed by co-immunoprecipitation. Samples were 
immunoprecipitated (IP) with an anti-FLAG antibody, followed by Western blot analysis with 
an antibody against C. Western blot images were quantified by densitometric analysis. Data 
are mean±s.e.m. of three independent experiments. Arrows, mutants with conserved binding 
to R subunits. Differences are statistically significant by two-way ANOVA. *P<0.05, **P<0.01 
and ****P<0.0001 vs. WT basal by Bonferroni´s post hoc test. Representative Western blot 
images are shown in Supplementary Data, Fig. 1 (23). 
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Fig. 3. Effect of PRKACA mutations on PKA activity against a synthetic substrate. 
HEK293A cells were co-transfected with RI or RIIand either wild-type (WT) or mutant C 
subunits. PKA activity in cell lysates was then measured against an artificial peptide 
substrate (kemptide) in the presence or absence of cAMP (40 M). The PKA activity 
measured in cells transfected with the empty expression vector (pcDNA) was subtracted. 
Data are mean±s.e.m. of three independent experiments. Data are statistically significant by 
two-way ANOVA. *P<0.05, ***P<0.001 vs. WT basal and ##P<0.01, ###P<0.001 vs. WT 
stimulated with cAMP by Bonferroni´s post hoc test. 
 
Fig. 4. PRKACA mutations affect substrate specificity as revealed by 
phosphoproteomics analysis. HEK293A cells were co-transfected with RII and either 
wild-type (WT) or mutant C subunits and labeled with light amino acids (WT) or heavy 
amino acids (mutant). Protein lysates from these cells were then proteolytically fragmented 
and the resulting phosphopeptides were immunoprecipitated using a phospho-PKA substrate 
antibody recognizing the RR/KXpS/T consensus.  Phosphopeptides were separated and 
detected by nanoscale liquid chromatography coupled to tandem mass spectrometry (nano 
LC-MS/MS). Depicted are scatter plots showing the abundance of the detected 
phosphopeptides in the mutant relative to wild-type samples of three independent 
experiments. The sequence logos report, for each mutant, the relative amino acid 
preferences around the consensus motif (RR/KXpS/T) for both hypo- (left) and 
hyperphosphorylated (right) sequences, calculated from the phosphopeptides. Values are 
expressed as log10-odds of the significance of overrepresentation versus the significance of 
underrepresentation, which are calculated using the binomial probability of residue 
frequencies. 
 
Fig. 5. Effect of PRKACA mutations on histone H1.4 phosphorylation in HEK293A 
cells. HEK293A cells were co-transfected with wild-type (WT) or mutant PKA C and the 
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RIIsubunit. Histone H1.4 phosphorylation was probed by Western blot analysis with an 
antibody specifically recognizing H1.4 phosphorylated at Ser36. A Western blot analysis for 
total histone H.1.4 was used as loading control. Western blot images were quantified by 
densitometric analysis. The adenylyl cyclase activator forskolin (10 M) was used to induce 
maximal PKA activity. Data are mean±s.e.m of three independent experiments. Differences 
are statistically significant by two-way ANOVA. *** P<0.001 vs. WT basal and # P<0.05 vs. 
WT forskolin by Bonferroni´s post hoc test. 
 
Fig. 6. Effect of PRKACA mutations on histone H1.4 phosphorylation in tumor (CPA) 
samples from patients with adrenal Cushing´s syndrome. Histones were extracted from 
CPAs with or without PRKACA mutations and analyzed by Western blot analysis with an 
antibody specifically recognizing H1.4 phosphorylated at Ser36. A Western blot analysis for 
total histone H1.4 was used as loading control. Western blot images were quantified by 
densitometric analysis. Quantified data are mean±s.e.m of 3 and 4 CPAs carrying the L206R 
mutation or with PRKACA wild-type (WT), respectively. Differences are statistically significant 
by unpaired t-test (** P=0.009). 
 
Table 1. List of somatic PRKACA mutations identified so far in CPAs of patients with overt 
Cushing’s syndrome. Bold, studies by our group. 
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Tables 
 
Mutation Frequency (n mutated/total) Reference 
L206R 
36% (21/59) 
60% (33/55) 
67% (84/126) 
35% (13/37) 
23% (3/13) 
34% (22/64) 
31% (11/35) 
(10) 
(16) 
(14) 
(15) 
(17) 
(11) 
(18) 
199_200insW 2% (1/59) (10) 
200_201insV 5% (3/64) (11) 
S213R+insIILR 2% (1/64) (11) 
W197R 3% (1/39) (12) 
d244-248+E249Q 3% (1/39) (12) 
E32V 3% (1/39) (12) 
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